Catalent Expert to Present Strategies for Improved Oral Delivery for Poorly Soluble and Permeable Drugs
Somerset, NJ, January 16, 2012 — Irena McGuffy, Manager, R&D Formulations for Catalent Pharma Solutions, will present “Selecting the Right Enabling Technology for Poorly Soluble Compounds” at eXL Pharma’s Enhancing Drug Bioavailability & Solubility Conference being held in Boston, MA on January 25, 2012. The conference focuses on novel formulation strategies for maximizing bioavailability, optimizing time-to-market, and lifecycle management of current and future drug products. Ms. McGuffy’s presentation will cover such areas as:
- Approaches to selection of the appropriate drug delivery technology;
- Advantages and challenges associated with each drug delivery option; and
- Commercial availability and speed to market.
Catalent has proven expertise in overcoming bioavailability and solubility challenges with an array of drug delivery technologies to bring more products to market faster as better treatments. Ms. McGuffy’s presentation will also cover particle engineering, hot melt extrusion, nano structures, lipid-based delivery systems ( softgels and Vegicaps®capsules ), and modified/targeted delivery options, such as film coated dosage forms.
Ms. McGuffy joined Catalent in 2007 with a background in product development, specifically in controlled release solid dosage form development and formulation of poorly soluble compounds. Ms. McGuffy is a registered pharmacist with a Bachelor’s degree in Pharmacy and a Master’s degree in Pharmaceutical Sciences from the University of Zagreb, Croatia. She is a member of the American Association of Pharmaceutical Sciences.
For more information on this event, please visit: www.exlpharma.com/events .
To schedule an interview with Ms. McGuffy, during or after the Enhancing Drug Bioavailability & Solubility Conference, please contact Patricia McGee at
To receive a copy of this presentation after the event, please visit us at www.catalent.com .
Click here for more information on how Catalent can help solve the most complex bioavailability challenges to help deliver better treatments.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.